Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

The primary purpose of this study is to evaluate the efficacy and safety of WX-0593 vs. crizotinib in patients with ALK-positive non-small cell lung cancer who had not received prior systemic

  • 0 views
  • 26 Jan, 2021
  • 1 location
Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

To observe the safety, tolerability and clinical effects of crizotinib combined with etoposide capsule followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) for patients

  • 1 views
  • 22 Jan, 2021
  • 1 location
Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

The main purpose of the study is to evaluate safety and efficacy of Alkotinib capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib.While exploring the relationship between biomarkers and drug efficacy and safety.

  • 0 views
  • 25 Jan, 2021
  • 1 location
ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer Study

The purpose of this study is to find out how effective the combination of crizotinib and fulvestrant is in shrinking lobular breast cancer tumours. The investigators will also be assessing the

HER2
erbb2
ROS1
measurable disease
cancer chemotherapy
  • 2 views
  • 25 Jan, 2021
  • 1 location
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease

neurofibromatosis type 2
measurable disease
schwartz
MRI Scan
absolute neutrophil count
  • 0 views
  • 10 Feb, 2021
  • 14 locations
Talazoparib and Palbociclib Axitinib or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors TalaCom Trial

This phase Ib trial is to find out the best dose, possible benefits and/or side effects of talazoparib when given in combination with palbociclib, axitinib, or crizotinib in treating patients

  • 0 views
  • 28 Jan, 2021
  • 1 location
Lorlatinib Combinations in Lung Cancer

This research study is evaluating Lorlatinib in combination with Crizotinib or Binimetinib as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1

lymphoma
measurable disease
combinations
tyrosine
ros1 rearrangement
  • 0 views
  • 25 Jan, 2021
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a

congestive heart failure
metastasis
adjuvant chemotherapy
tumor cells
ct scan
  • 387 views
  • 25 Jan, 2021
  • 1093 locations
Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

To evaluate the efficacy and safety of TQ-B3139 in subjects with ALK-positive non-small cell lung cancer that have demonstrated progression during or after crizotinib treatment whether or not

  • 14 views
  • 23 Jan, 2021
  • 1 location
Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

To evaluate the efficacy and safety of TQ-B3139 versus crizotinib in subjects with ALK-positive NSCLC that have received one chemotherapy regimen and have not received ALK inhibitor.

  • 1 views
  • 23 Jan, 2021
  • 1 location